All Stories

Odyssey abandons IPO plans in latest sign of tough environment for biotech listings

Odyssey Therapeutics has bailed on its long-awaited public listing in further evidence that the IPO window remains firmly shut for now.

Jun 10, 2025 - 13:40
 0
Odyssey abandons IPO plans in latest sign of tough environment for biotech listings
Odyssey Therapeutics has bailed on its long-awaited public listing in further evidence that the IPO window remains firmly shut for now.
Read More

Tags:

Previous Article

Sustainable dealership development and management - an AM webinar

Next Article

GSK snags longtime Sanofi exec to lead vaccine and infectious disease R&D

Related Posts

A Cost-Effective Breakthrough in Genome-Wide DNA Methylation Sequencing

A Cost-Effective Breakthrough in Genome-Wide DNA Methyl...

May 19, 2025  0

Accropeutics' TYK2/JAK1 inhibitor hits psoriasis endpoints in Chinese biotech's first phase 2 win

Accropeutics' TYK2/JAK1 inhibitor hits psoriasis endpoi...

May 21, 2025  0

FDA clears first AI tool for breast cancer risk prediction from startup Clairity

FDA clears first AI tool for breast cancer risk predict...

Jun 5, 2025  0